A Phase 4 interventional study of FOLFERI and Folferi and celecoxib in Colon Cancer Stage, sponsored by Sherief Abd-Elsalam. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-04-20.
Sponsored by Sherief Abd-Elsalam · Phase 4, Interventional, and Treatment
Among 37 studies in Colonic Neoplasms with a site in Egypt — 5 open to participants now, 5 under way, none of them phase 3. Colonic Neoplasms · Egypt.
Among the 37 studies in Colonic Neoplasms with a site in Egypt, this one is the 18th largest by planned enrollment of the 30 interventional ones, is one of 3 that started in 2018, is one of 2 in phase 4, and was the 9th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.
This study's planned enrollment of 50 is below the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Browse Colonic Neoplasms studies →5 of the 37 studies in Colonic Neoplasms with a site in Egypt are open now, in 1 country. Each count lists the studies.
Of the 326 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 71 (22%) stop at 75 or younger; 19 take children under 18; 34 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →37 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2018.
Median enrollment 60 across the 30 interventional studies, 60 across the 6 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
3 of 37 have an industry lead sponsor. The 10 most frequent:
Sherief Abd-Elsalam is the lead sponsor of 50 studies on the registry; 23 are open to participants now.
Sherief Abd-Elsalam has 2 studies filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 37 studies in Colonic Neoplasms with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
The study aimed at evaluation of anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer
The primary aim of the study is to evaluate the anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FOLFERI regien
Drug: FOLFERI
FOLFERI and celecoxib
Drug: Folferi and celecoxib
FOLFERI regimen
Folferi regimen and celecoxib
number of patients with improved radiology
number of patients with improved radiology
Time frame: 6 months
Plan to share: No
Started Aug 2018 (actual). Primary completion is estimated for Aug 2025, 84 months after the start.
Of 16 phase 4 interventional studies under Colonic Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 105. This study's planned 84 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sherief Abd-Elsalam